Royalty Pharma Declares Third Quarter 2025 Dividend
NEW YORK, NY, July 18, 2025 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.
News
Royalty Pharma published press releases by date and/or category
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
NEW YORK, NY, July 17, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately.
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
NEW YORK, NY, July 16, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open.
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
NEW YORK, NY, June 24, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million.
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, NY, June 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.
Royalty Pharma Completes the Acquisition of Its External Manager
NEW YORK, NY, May 16, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”).
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, NY, May 13, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
NEW YORK, NY, May 12, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma’s 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company.
Royalty Pharma Reports First Quarter 2025 Results
NEW YORK, NY, May 8th, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.
Royalty Pharma Declares Second Quarter 2025 Dividend
NEW YORK, NY, April 21, 2025 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share.
